Sign In

Vineet K. Singh

Senior Manager in Corporate Strategy at TTEC

Vineet K. Singh is currently the Senior Manager of Corporate Strategy and Portfolio Lead for Healthcare at TTEC, a position he has held since July 2022. Based in New Delhi, India, he specializes in the US healthcare ecosystem, particularly in health insurance and payer segments, including both private and government programs like Medicare and Medicaid. His work focuses on improving healthcare outcomes through IT and customer experience strategies, navigating complex regulations, and optimizing technology for better patient care, especially in chronic disease management.1

In his role, Singh is responsible for enhancing ecosystem outcomes while achieving the financial objectives of TTEC. He employs personalized and intent-driven marketing strategies, empowers business development representatives with the necessary tools, and experiments with sales processes to drive revenue impact. His expertise also includes utilizing digital health technologies and data insights to identify and address population health needs.1

Singh has a background that encompasses various roles in strategy building, performance marketing, and corporate entrepreneurship, and he actively engages in community initiatives to promote entrepreneurship and economic empowerment.1

Highlights

Jun 5 · linkedin

Another breakthrough in the hearing care ecosystem!

A groundbreaking gene therapy trial, aimed at treating hearing loss in children, marks a pivotal moment in medical science, restoring hearing function in five children who were treated for bilateral hearing loss.

Traditionally, cochlear implants have been one of the primary solutions for those born deaf, offering hope and improved quality of life. However, this new gene therapy could significantly alter the landscape, offering an alternative that might restore hearing, potentially in a more natural way.

Notably, over 430 million people around the world are affected by disabling hearing loss, of which congenital deafness constitutes about 26 million of them. And up to 60% of childhood deafness is caused by genetic factors!

Time and again, it had been proven how technology could render the market dynamics entirely changed. It would be interesting how the future unfolds for billion$+ cochlear implant market, constituting key players like Cochlear, Advanced Bionics, MED-EL.

https://lnkd.in/gw7PwsqP #genetherapy #deafness #hearingloss #medicalbreakthrough #MassEyeandEar #FudanUniversity

Mar 28 · linkedin

The phrase "Ozempic babies" is emerging as a social media frenzy, attributed to surprise pregnancies experienced by women taking the drugs Ozempic and Wegovy.

Reddit, Inc. and TikTok are abuzz with users sharing their "Ozempic Babies" stories, strikingly even for those who previously believed they couldn't conceive or were on birth-control.

For quick background: While Ozempic is approved for Type 2 diabetes, with weight loss as a side effect, the other version of the drug — Wegovy — is FDA-approved for people with obesity. While they’re the same drug, Semaglutide, they’re under different brand names, have a slightly different dosing schedule, and both are manufactured by Novo Nordisk.

Similarly, Eli Lilly and Company offers its parallel brands, Mounjaro for diabetes, and Zepbound for weight-loss.

With significant "off-label" use already reported for these drugs, now we see this another phenomenon with potential impacts on fertility. Notably, the occurrence has become so significant that Novo Nordisk has set up an FDA-approved Wegovy Pregnancy Registry, allowing patients and providers to share details of pregnancies while taking their medication.

Industry sources report that these drugs could garner >$100 billion in revenue over the next decade, already propelling Novo Nordisk's valuation past $500 billion.

Aiming to capitalize on Novo Nordisk's success, Indian drugmakers— SUN PHARMA, Cipla, Dr. Reddy's Laboratories, and Lupin—some of the world's largest generic drugmakers, are reportedly developing generic versions of Wegovy.

Amidst these evolving business and medical landscape, the future of Wegovy and all its 'upcoming' alternatives remains to be seen.

#wegovy #ozempicbabies #weightloss #diabetes

Related Questions

What are Vineet K. Singh's key achievements at TTEC?
How does Vineet K. Singh integrate IT and CX strategies in healthcare?
What are Vineet K. Singh's interests outside of work?
How has Vineet K. Singh contributed to the Techstars Startup Weekend?
What are Vineet K. Singh's main responsibilities as Portfolio Lead in Healthcare at TTEC?
Vineet K. Singh
Vineet K. Singh, photo 1
Vineet K. Singh, photo 2
Add to my network

Experience

Senior Manager, Corporate Strategy and Portfolio Lead for Healthcare at TTEC since July 2022
Strategic Initiatives for MedTech Engineering and R&D at HCL Technologies from June 2020 to June 2022

Education

PGDM in Marketing from Institute of Management Technology, Ghaziabad (2018-2020), B.Tech. in Chemical Engineering from Institute of Engineering and Technology (2010-2014)

Location

New Delhi, Delhi, India